Comparison Of Atherosclerotic Risk Factors In Patients With Secondary Amylodosis And Nephrotic Syndrome
Özet
Objective
we aimed to compare atherosclerotic risk factors in patients with secondary amyloid and nephrotic syndrome with proteinuria.
Method
In the nephrology outpatient clinic, patients with nephrotic syndrome clinic and proteinuria underwent diagnostic biopsy of the kidney and other tissues thought to be infiltrated with amyloidosis. Demographic, clinical, laboratory and biopsy results of the people included in the study were evaluated.
Results
A total of 89 people were included in the study (secondary amyloidosis: 12 female and 18 men, nephrotic syndrome: 12 female and 17 men, healthy control: 15 female and 15 men, mean age respectively: 46.5±14.2 year, 45.3±13.3 year, 45.4±5.7 year), Total cholesterol, triglyceride, low density lipoprotein cholesterol (LDL-C), lipoprotein a (Lp a), apo-lipoprotein Al (apo Al), apo-lipoprotein B (apo B), apo-lipoprotein E (apo E), C- reactive protein (CRP) and fibrinogen levels in nephrotic syndrome and secondary amylodosis patients were significantly higher than the control group whereas high density lipoprotein cholesterol (HDL-C) levels were lower (p<0.01). When nephrotic syndrome and secondary amyloidosis patients were compared, total cholesterol, triglyceride, LDL-C, HDL-C, apo Al, apo B and apo E levels were higher in the nephrotic syndrome group compared to the secondary amyloidosis group (p<0,05). There were no differences in CRP, fibrinogen and Lp(a) levels (p>0.05).
Conclusion
Our data showed that atherosclerotic risk factors were significantly higher in patients with nephrotic syndrome and secondary amyloidosis. Patients with amyloidosis should be closely monitored for other atherosiderotic risk factors as well as amyloid accumulated in the organs
Referanslar
Politano SA, Colbert GB, Hamiduzzaman N. Nephrotic Syndrome. Prim Care. 2020;47(4):597-613. doi: 10.1016/j.pop.2020.08.002.
Kodner C. Diagnosis and Management of Nephrotic Syndrome in Adults. Am Fam Physician. 2016;93(6):479-85. PMID: 26977832.
Smith RR, Hutchins GM. Ischemic heart disease secondary to amyloidosis of intramyocardial arteries. Am J Cardiol. 1979;44(3):413-7. doi: 10.1016/0002-9149(79)90389-8.
Hamer JP, Janssen S, van Rijswijk MH, et al. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echocardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J. 1992;13(5):623-7. doi: 10.1093/oxfordjournals.eurheartj.a060225.
Go AS, Tan TC, Chertow GM, et al. Primary Nephrotic Syndrome and Risks of ESKD, Cardiovascular Events, and Death: The Kaiser Permanente Nephrotic Syndrome Study. J Am Soc Nephrol. 2021;32(9):2303-2314. doi: 10.1681/ASN.2020111583.
Wheeler DC, Bernard DB. Lipid abnormalities in the nephrotic syndrome: causes, consequences, and treatment. Am J Kidney Dis. 1994;23(3):331-46. doi: 10.1016/s0272-6386(12)80994-2.
Radhakrishnan J, Appel AS, Valeri A, et al. The nephrotic syndrome, lipids, and risk factors for cardiovascular disease. Am J Kidney Dis. 1993;22(1):135-42. doi: 10.1016/s0272-6386(12)70179-8.
Martinez-Naharro A, Baksi AJ, Hawkins PN, et al. Diagnostic imaging of cardiac amyloidosis. Nat Rev Cardiol. 2020;17(7):413-426. doi: 10.1038/s41569-020-0334-7.
Srinivas KV, Neverov NI, Kolonduk NV, et al. Lipidy krovi pri amiloidoze pochek [Blood lipids in renal amyloidosis]. Urol Nefrol (Mosk). 1993;(1):28-31.
Ordoñez JD, Hiatt RA, Killebrew EJ, et al. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int. 1993;44(3):638-42. doi: 10.1038/ki.1993.292.
Ongajyooth L, Sirisalee K, Laohaphand T et al. Lipoprotein abnormalities in adult nephrotic syndrome. J Med Assoc Thai. 1993;76(9):512-20. PMID: 7964258.
Attman PO, Alaupovic P. Pathogenesis of hyperlipidemia in the nephrotic syndrome. Am J Nephrol. 1990;10 Suppl 1:69-75. doi: 10.1159/000168197.
Stenvinkel P, Berglund L, Ericsson S, et al. Low-density lipoprotein metabolism and its association to plasma lipoprotein(a) in the nephrotic syndrome. Eur J Clin Invest. 1997;27(2):169-77. doi: 10.1046/j.1365-2362.1997.930641.x.
Paisley KE, Beaman M, Tooke JE, et al. Endothelial dysfunction and inflammation in asymptomatic proteinuria. Kidney Int. 2003; 63(2):624-33. doi: 10.1046/j.1523-1755.2003.00768.x.
Cabana VG, Feng N, Reardon CA, et al. Influence of apoA-I and apoE on the formation of serum amyloid A-containing lipoproteins in vivo and in vitro. J Lipid Res. 2004;45(2):317-25. doi: 10.1194/jlr.M300414-JLR200.
Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41-52. doi: 10.1016/j.kint.2016.02.026.
Linton MF, Fazio S. National Cholesterol Education Program (NCEP)- the third Adult Treatment Panel (ATP III). A practical approach to risk assessment to prevent coronary artery disease and its complications. Am J Cardiol. 2003;92(1A):19i-26i. doi: 10.1016/s0002-9149(03)00505-8.
Kronenberg F, Steinmetz A, Kostner GM, et al. Lipoprotein(a) in health and disease. Crit Rev Clin Lab Sci. 1996;33(6):495-543. doi: 10.3109/10408369609080056.
Reyes-Soffer G, Westerterp M. Beyond Lipoprotein(a) plasma measurements: Lipoprotein(a) and inflammation. Pharmacol Res. 2021;169:105689. doi: 10.1016/j.phrs.2021.105689.
Unlü Y, Karapolat S, Karaca Y, et al. Comparison of levels of inflammatory markers and hemostatic factors in the patients with and without peripheral arterial disease. Thromb Res. 2006;117(4):357-64. doi: 10.1016/j.thromres.2005.03.019.
Sengul S, Arat Z, Ozdemir FN. Renal amyloidosis is associated with increased mortality in hemodialysis patients. Artif Organs. 2004;28(9):846-52. doi:10.1111/j.1525-1594.2004.00063.x.
Kaaroud H, Harzallah A, Hajji M, et al. Renal Amyloidosis: Epidemiological, Clinical, and Laboratory Profile in Adults from One Nephrology Center. Int J Nephrol. 2022;2022:8493479. doi: 10.1155/2022/8493479.
Cengiz K, Bakan A, Yilmaz H. Lipoprotein abnormalities in patients with secondary renal amyloidosis. Int Urol Nephrol. 2001;32(4):615-9. doi: 10.1023/a:1014476407047.
Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 2000;7(1):64-9. doi: 10.1097/00062752-200001000-00012.
Sack GH Jr. Serum Amyloid A (SAA) Proteins. Subcell Biochem. 2020;94:421-436. doi: 10.1007/978-3-030-41769-7_17.
Sack GH Jr. Serum amyloid A- a review. Mol Med. 2018;24(1):46. doi: 10.1186/s10020-018-0047-0.
